Nluc Reporter Cell Line - E0771

The E0771 cell line is a well-established murine breast cancer model derived from a spontaneous mammary tumor in C57BL/6 mice. Due to its immunocompetent background, this cell line is highly relevant for studying tumor biology, immunotherapy responses, and metastatic processes. E0771 cells exhibit an aggressive growth pattern and retain key characteristics of triple-negative breast cancer, making them a valuable tool for preclinical research. Its compatibility with syngeneic mouse models allows researchers to study tumor microenvironment interactions, immune cell infiltration, and therapeutic efficacy in a physiologically relevant setting. This cell line has been widely used in studies of chemotherapy, radiotherapy, and novel immunotherapies, providing crucial insights into treatment resistance mechanisms and potential combination therapy strategies.

The Nluc reporter cell line-E0771 incorporates NanoLuc luciferase (Nluc), a revolutionary bioluminescent reporter gene that offers superior sensitivity and stability compared to traditional luciferases. This genetic modification enables real-time, non-invasive monitoring of tumor dynamics in vivo through bioluminescence imaging (BLI), allowing researchers to quantitatively track tumor growth, metastasis, and response to treatment with exceptional precision. The application of this reporter cell line significantly enhances longitudinal studies, reduces the need for endpoint time points, and allows for repeated measurements within the same animal cohort. In immunotherapy research, the Nluc-E0771 model facilitates high-throughput screening of immune checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses by providing dynamic readouts of tumor burden and immune-mediated clearance.